TNFR2/CCR8双特异性抗体通过耗尽Ti-Tregs增强抗瘤活性,并增强效应因子CD8+ T细胞功能
Ran Wang1, Jiefang Xu1, Shipeng Cheng2
1Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Oncoimmunology
|April 28, 2025
概括
一种新的双特异性抗体FT10-Fab精确地准并消耗瘤透调节T细胞 (Ti-Tregs). 这种方法可以增强抗瘤免疫力,并且在结合PD-1阻断用于癌症免疫治疗时显示出有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 瘤透调控T细胞 (Ti-Tregs) 抑制抗瘤免疫反应.
- 目前用于Treg调制的策略缺乏精度,并且由于Treg异质性而面临挑战.
- 针对特定的Treg标志物对于有效的癌症免疫疗法至关重要.
研究的目的:
- 开发一种用于选择性耗尽Ti-Tregs的双特异性抗体.
- 评估针对TNFR2和CCR8.8的双特异性抗体FT10-Fab的疗效.
- 为了研究FT10-Fab与PD-1阻断的联合治疗.
主要方法:
- 开发一种针对TNFR2和CCR8.8的双特异性抗体 (FT10-Fab).
- 在多个瘤模型中的体内研究.
- 流细胞测量分析以评估免疫细胞群.
- 使用PD-1阻断的组合疗法研究.
主要成果:
- 在瘤模型中,FT10-Fab有效降低了Ti-Tregs,特别是TNFR2+CCR8+Tregs.
- 该抗体增加了CD8+T细胞的比例,并增强了抗瘤免疫力.
- 与单一疗法相比,FT10-Fab显示出更高的疗效.
- 与PD-1阻断的结合导致了协同治疗效应.
结论:
- 使用双特异性TNFR2/CCR8抗体FT10-Fab精确消耗Ti-Tregs是一种可行的癌症免疫治疗策略.
- FT10-Fab利用CD8+ T细胞进行抗瘤功能,并诱导免疫记忆.
- 将FT10-Fab与抗PD1疗法结合起来,可以增强抗瘤效果,并提供一个有前途的治疗方法.
相关概念视频
Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
Cytotoxic T Cells-mediated Immune Response
722
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
722
T Cell Activation and Clonal Selection
526
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
526
T Cell Types and Functions
615
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
615
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


